Patient info Open main menu

Tixylix Childrens dry & Tickly Cough 15%v/v syrup – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: General sale (GSL) Details

Medicine strength:
150 microlitre/ml
Contains active substance:
ATC code:

Summary of Product Characteristics (SmPC) - Tixylix Childrens dry & Tickly Cough 15%v/v syrup

1 NAME OF THE MEDICINAL PRODUCT

Tixylix Children’s Dry & Tickly Cough 15%v/v Syrup

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient:

Glycerol 0.75ml per 5 ml

Excipient(s) with known effect:

Liquid maltitol (Lycasin) 2.06g/5ml dose.

Sodium benzoate (E 211) 10mg per 5ml dose.

Propylene glycol (E 1520) 4.7mg per 5ml dose.

Lemon flavour (contains propylene glycol E1520)

Honey flavour (contains propylene glycol E1520)

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Syrup

A clear viscous liquid

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the relief of dry tickly coughs

4.2 Posology and method of administration

For oral administration.

Children 3 months to under 1 year: One 5 ml spoonful three to four times a day

Children 1 to 5 years: Two 5 ml spoonfuls three to four times a day

Allow 3 to 4 hours between doses.

Children under 3 months: Not recommended

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Not recommended for children under 3 months.

If symptoms persist for more than 3 days consult your doctor.

Important information about some of the ingredients:

This medicine contains:

  • Sodium benzoate (E211), 10mg per 5ml dose.
  • Maltitol may have a mild laxative effect. Calorific value

    2.3Kcal/g. If you have been told by your doctor that your child is intolerant to some sugars, contact your doctor before taking this medicinal product.

    Patients with rare hereditary problems of fructose intolerance should not take this medicine.

  • This medicine contains 4.7mg propylene glycol (E1520) in

    each 5ml dose.

  • Less than 1mmol sodium (23mg) per 5ml dose, that is to say

    essentially “sodium-free”.

4.5 Interaction with other medicinal products and other forms of interaction

No known drug interactions exist.

4.6 Fertility, pregnancy and lactation

No data are available for glycerol on exposed pregnancies or use during lactation. Caution should be exercised when prescribing during pregnancy.

4.7 Effects on ability to drive and use machines

On the basis of the known pharmacodynamic and adverse event profile for glycerol, this medicine has no major influence on the ability to drive and use machinery.

4.8 Undesirable effects

No adverse effects known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for ‘MHRA Yellow Card’ in the Google Play or Apple App Store.

4.9 Overdose

Overdosage with this product may possibly cause diarrhoea. Treatment should be symptomatic.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Glycerol has demulcent properties and may possibly block sensory cough receptors in the respiratory tract. ATC code: R05DB

5.2 Pharmacokinetic properties

None stated.

5.3 Preclinical safety data

None stated.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Liquid maltitol (Lycasin) (E965) Hydroxyethyl cellulose (E1525) Sodium Benzoate (E211) Citric Acid Monohydrate (E330) Sodium Citrate (E331)

Lemon flavour (contains propylene glycol E1520) Honey flavour (contains propylene glycol E1520) Purified Water

6.2 Incompatibilities

None stated.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Keep the container tightly closed

Do not store above 25°C

6.5 Nature and contents of container

Container: Amber-coloured glass sirop bottle Closure: Tamper evident cap with Tri-seal liner. Measuring spoon provided.

Pack size: 100ml

6.6 Special precautions for disposal

Not applicable.

7 MARKETING AUTHORISATION HOLDER

Thornton & Ross Ltd.

Linthwaite,

Huddersfield,

HD7 5QH, UK

8 MARKETING AUTHORISATION NUMBER(S)

PL 00240/0583

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

03/10/2023

10 DATE OF REVISION OF THE TEXT

03/10/2023

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00240/0583

Last revision stated in the text: 3 October 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Tixylix Childrens dry & Tickly Cough 15%v/v syrup

Prescription needed? No, general sale list medicine (GSL) – also sold outside pharmacies
Active substance Glycerol
Strength 150 microlitre/ml
Pharmaceutical form Oral solution
A clear viscous liquid
How is it taken Oral
Excipients Liquid maltitol (Lycasin) (E965) Hydroxyethyl cellulose (E1525) Sodium Benzoate (E211) Citric Acid Monohydrate (E330) Sodium Citrate (E331), Lemon flavour (contains propylene glycol E1520) Honey flavour (contains propylene glycol E1520) Purified Water
Pack sizes 100 ml
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 36 months
Storage Keep the container tightly closed
Do not store above 25°C
Drug group (ATC)
  1. A Alimentary tract and metabolism drugs
    1. A06 Drugs for constipation
      1. A06A Drugs for constipation
        1. A06AX Other drugs for constipation
          1. A06AX01 glycerol
Marketing authorisation PL 00240/0583 (first authorised 3 October 2023)
Marketing authorisation holder Thornton & Ross Ltd.
Codes GTIN 5011309064216 · BNF 03090200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.